MT 8554

Drug Profile

MT 8554

Alternative Names: MT8554

Latest Information Update: 28 Feb 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Mitsubishi Tanabe Pharma Corporation
  • Class Neuroprotectants
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Diabetic neuropathies; Vasomotor symptoms
  • Phase I Neurological disorders

Most Recent Events

  • 20 Mar 2018 Mitsubishi Tanabe Pharma plans the phase I MT-8554 DQT safety trial of MT 8554 on the QT/QTc interval (In volunteers) in United Kingdom (PO), in March 2018 (NCT03471130)
  • 29 Jan 2018 Mitsubishi Tanabe Pharma completes a phase I mass-balance trial in Healthy volunteers in United Kingdom (PO) (NCT03381404)
  • 22 Dec 2017 Mitsubishi Tanabe Pharma plans a phase I mass-balance trial in Healthy volunteers in United Kingdom (PO) (MT-8554-E07; NCT03381404)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top